ketoxyme 100 mg/ml solution for use in drinking water
andersen, s.a. - ketoprofen - solution for use in drinking water - 100 milligram(s)/millilitre - ketoprofen - pigs, sheep - n.s.a.i.d.
an 1004 eo gas 4
andersen products, inc - ethylene oxide - gas - 97% - ethylene oxide 97% - disinfectants (for agents used on object)
an 7916 anprolene gas
andersen products, inc - ethylene oxide - gas - 97% - ethylene oxide 97% - disinfectants (for agents used on object)
ketoxyme 100 mg/ml sol. for drinking water
andersen s.a. - ketoprofen 100 mg/ml - solution for use in drinking water - 100 mg/ml - ketoprofen 100 mg/ml - ketoprofen - pig
colixyme 22,5 miu/g pwdr. for drinking water
andersen s.a. - colistin sulfate - eq. colistin 22,5 10*6 iu/g - powder for use in drinking water - colistin
floxyme 50 mg/ml or. sol. (conc.)
andersen s.a. - florfenicol 50 mg/ml - concentrate for oral solution - florfenicol
sterilizer, gas, ethylene oxide
steriflex pty ltd - 13740 - sterilizer, gas, ethylene oxide - to be used to sterilise heat and moisture sensitive medical devices
ophthalmic anaesthesia needle
surgivision pty ltd - 47610 - ophthalmic anaesthesia needle - sp.eye is intended for use as an aid for intravitreal injection with provision for sharps safety. it may be used for any medication licensed for trans pars plana injection into the eye using a 30-gauge needle.
endari- glutamine powder, for solution
emmaus medical, inc. - glutamine (unii: 0rh81l854j) (glutamine - unii:0rh81l854j) - glutamine 5 g - endari is indicated to reduce the acute complications of sickle cell disease in adult and pediatric patients 5 years of age and older. none risk summary there are no available data on endari use in pregnant women to inform a drug-associated risk of major birth defects and miscarriage. animal reproduction studies were not conducted with endari. adverse outcomes in pregnancy occur regardless of the health of the mother or the use of medications. the background risk of major birth defects and miscarriage for the indicated population are unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. risk summary there are no data on the presence of endari in human milk, the effect on the breastfed infant or the effect on milk production. the developmental and health benefits from breastfeeding should be considered along with the mother's clinical need for endari and any potential advers
zontivity
merck sharp dohme limited - vorapaxar sulfate - myocardial infarction - antithrombotic agents - zontivityis indicated for the reduction of atherothrombotic events in adult patients with- a history of myocardial infarction (mi)co-administered with acetylsalicylic acid (asa) and, where appropriate, clopidogrel; or- symptomatic peripheral arterial disease(pad), co-administered with acetylsalicylic acid (asa) or, where appropriate, clopidogrel.